Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019

Ibrutinib + Venetoclax for Frontline CLL

December 24th 2019

MRD Testing for CLL

December 24th 2019

Obinutuzumab + Venetoclax for Frontline CLL

December 24th 2019

Comparison of BTK Inhibitors for CLL

December 24th 2019

Toxicities With BTK Inhibitors for CLL

December 24th 2019

Frontline Antibodies With BTK Inhibitors for CLL

December 24th 2019

Up-front Ibrutinib Versus FCR for Patients With CLL

December 24th 2019

Risk Assessment in Newly Diagnosed CLL

December 24th 2019

Dr. Olin on the Utility of Venetoclax in AML

December 23rd 2019

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the utility of venetoclax in acute myeloid leukemia.

CAR T-Cell Therapy as an Outpatient Treatment Option

December 23rd 2019

Anticipation of ZUMA-7 Results

December 23rd 2019

Next-Generation CAR T Therapy

December 23rd 2019

Expanded Use of CAR T Therapy in Hematologic Malignancies

December 23rd 2019

The TRANSCEND-NHL-001 Trial

December 23rd 2019

CAR T Associated Cytokine Release Syndrome

December 23rd 2019

Real-World Data and CAR T Therapy

December 23rd 2019

CAR-T Therapy Treatment Variables

December 23rd 2019

High-Risk Lymphoma: The ZUMA-1 and SCHOLAR-1 Trials

December 23rd 2019